From a molecular pharmacy perspective, Relafen 750 (the active ingredient) represents a fascinating illustration of how targeted drug action can reduce inflammation. Its mechanism primarily involves the inhibition of cyclooxygenase (prostaglandin-synthesizing enzymes), specifically COX-2, reducing the synthesis of pain messengers. This targeted inh

From a biochemical pharmacy viewpoint, Relafen 750, containing naproxen, embodies a fascinating case study in medication action. Its chief mechanism involves blocking cyclooxygenase (COX) enzymes, specifically COX-2, which results in reduced production of prostaglandins . This specific inhibition alleviates tenderness and pain associated with condi